| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shuai Liu, Yao-Hui Liu, Hong-Bo Ni, Jia-Jian Li, Ze-Tao Wu, Luo-Luo Wang, Yi Ruan and Xin-Hua Zhou |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Zhejiang Province Medicine and Health Science and Technology Project |
No. 2023KY239 |
| Zhejiang Province Traditional Chinese Medicine Science and Technology Plan Project |
No. 2024ZL949 |
|
| Corresponding Author |
Xin-Hua Zhou, Chief Physician, Professor, Department of Hepatobiliary and Pancreatic Surgery, Li Huili Hospital Affiliated to Ningbo University, No. 1111 Jiangnan Road, Yinzhou District, Ningbo 315000, Zhejiang Province, China. zhouxinhua1002@163.com |
| Key Words |
Transarterial chemoembolization; Hepatocellular carcinoma; Portal vein tumor thrombus; Programmed cell death protein-1; Propensity score matching; Lenvatinib |
| Core Tip |
This study evaluates the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib plus death protein-1 inhibitors (TACE-L-P) vs TACE combined with lenvatinib (TACE-L) in treating hepatocellular carcinoma with portal vein tumor thrombus (HCC-PVTT). The TACE-L-P regimen showed significantly improved overall survival, progression-free survival, and response rates compared to TACE-L. The safety profiles were comparable, with no severe treatment-related adverse events. These findings suggest that TACE-L-P may be a promising therapeutic option for HCC-PVTT patients. |
| Publish Date |
2025-06-20 08:05 |
| Citation |
<p>Liu S, Liu YH, Ni HB, Li JJ, Wu ZT, Wang LL, Ruan Y, Zhou XH. Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus. <i>World J Clin Oncol</i> 2025; 16(6): 106798</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i6/106798.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i6.106798 |
